Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis

Wiener Klinische Wochenschrift

Volumn 118, Issue 15-16, 2006, Pages 442-462

  Nairz, Manfred ^a   Weiss, Günter ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anemia of chronic disease; Anemia of critical illness; Hemochromatosis; Iron deficiency; Secondary iron overload

Indexed keywords

CARRIER PROTEIN; CD163 ANTIGEN; CD71 ANTIGEN; CERULOPLASMIN; CYTOCHROME B; DEFERASIROX; DEFEROXAMINE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROPORTIN 1; FERROUS GLUCONATE; HEMOJUVELIN; HEMOPROTEIN; HEPCIDIN; HFE PROTEIN; IRON; IRON CHELATING AGENT; IRON DEXTRAN; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; LIPOCALIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TRANSFERRIN RECEPTOR 2;

ANEMIA; BLOOD TRANSFUSION; CANCER RISK; CELL FUNCTION; CELL METABOLISM; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CRITICAL ILLNESS; DIAGNOSTIC IMAGING; GENE MUTATION; HEMOCHROMATOSIS; HUMAN; IMMUNE RESPONSE; INFECTION RISK; IRON CHELATION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON OVERLOAD; IRON THERAPY; IRON TRANSPORT; LIVER BIOPSY; NONHUMAN; PATHOPHYSIOLOGY; PHLEBOTOMY; PROTEIN FUNCTION; REVIEW;

ADOLESCENT; ADULT; ANEMIA; ANEMIA, IRON-DEFICIENCY; BIOPSY; CHRONIC DISEASE; CRITICAL ILLNESS; FEMALE; FETUS; FORECASTING; HEMOCHROMATOSIS; HOMEOSTASIS; HUMANS; INFANT, NEWBORN; IRON; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MUTATION; PREGNANCY; RISK FACTORS;

EID: 33748764432     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-006-0653-7     Document Type: Review

References (191)

1. Weiss G (2002) Iron and immunity: a double-edged sword. Eur J Clin Invest 32 [Suppl 1]: 70
2. Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117: 285
3. Pantopoulos K (2005) Regulation of Iron Metabolism. In: Weiss G VRG, Hershko C (eds) Anemia of chronic disease, Vol 30. CRC Press, Taylor & Francis Group, Boca Raton, p 1
4. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352: 1011
5. Pietrangelo A (2004) Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 350: 2383
6. Yano M, Hayashi H, Yoshioka K, Kohgo Y, Saito H, Niitsu Y, et al (2004) A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol 39: 570
7. Metwally MA, Zein CO, Zein NN (2004) Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol 99: 286
8. Theurl I, Zoller H, Obrist P, Datz C, Bachmann F, Elliott RM, et al (2004) Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J Infect Dis 190: 819
9. Gordeuk VR, Delanghe JR, Langlois MR, Boelaert JR (2001) Iron status and the outcome of HIV infection: an overview. J Clin Virol 20: 111
10. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F (1997) Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 96: 3300
11. Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT (1998) Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 97: 1461
12. Gaenzer H, Marschang P, Sturm W, Neumayr G, Vogel W, Patsch J, et al (2002) Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol 40: 2189
13. Turoczi T, Jun L, Cordis G, Morris JE, Maulik N, Stevens RG, et al (2003) HFE mutation and dietary iron content interact to increase ischemia/reperfusion injury of the heart in mice. Circ Res 92: 1240
14. Weinberg ED (1998) Patho-ecological implications of microbial acquisition of host iron. Reviews in Medical Microbiology 9: 171
15. Weinberg ED (1999) Iron therapy and cancer. Kidney Int [Suppl] 69: S131
16. Weiss G (2002) Iron, infection and anemia - a classical triad. Wien Klin Wochenschr 114: 357
17. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, et al (1998) The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 95: 1472
18. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, et al (1997) Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388: 482
19. McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, et al (2001) An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291: 1755
20. Shayeghi M, Latunde-Dada GO, Oakhill JS, Laftah AH, Takeuchi K, Halliday N, et al (2005) Identification of an intestinal heme transporter. Cell 122: 789
21. Poss KD, Tonegawa S (1997) Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci USA 94: 10919
22. Theurl I, Fritsche G, Ludwiczek S, Garimorth K, Bellmann-Weiler R, Weiss G (2005) The macrophage: a cellular factory at the interphase between iron and immunity for the control of infections. Biometals 18: 359
23. Weiss G (2002) Iron acquisition by the reticuloendothelial system. In: Templeton D (ed) Molecular and cellular iron transport. Marcel Dekker, New York, p 467
24. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al (2001) Identification of the haemoglobin scavenger receptor. Nature 409: 198
25. Hvidberg V, Maniecki MB, Jacobsen C, Hojrup P, Moller HJ, Moestrup SK (2005) Identification of the receptor scavenging hemopexin-heme complexes. Blood 106: 2572
26. Muckenthaler M, Gray NK, Hentze MW (1998) IRP-1 binding to ferritin mRNA prevents the recruitment of the small ribosomal subunit by the cap-binding complex eIF4F. Mol Cell 2: 383
27. Guo B, Phillips JD, Yu Y, Leibold EA (1995) Iron regulates the intracellular degradation of iron regulatory protein 2 by the proteasome. J Biol Chem 270: 21645
28. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al (2005) The iron exporter ferroportin/Slc40 al is essential for iron homeostasis. Cell Metab 1: 191
29. Wessling-Resnick M (2006) Iron imports. III. Transfer of iron from the mucosa into circulation. Am J Physiol Gastrointest Liver Physiol 290: G1
30. Conrad ME, Umbreit JN (2002) Pathways of iron absorption. Blood Cells Mol Dis 29: 336
31. Zoller H, Koch RO, Theurl I, Obrist P, Pietrangelo A, Montosi G, et al (2001) Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload. Gastroenterology 120: 1412
32. Creagh AL, Tiong JW, Tian MM, Haynes CA, Jefferies WA (2005) Calorimetric studies of melanotransferrin (p97) and its interaction with iron. J Biol Chem 280: 15735
33. Sekyere EO, Dunn LL, Rahmanto YS, Richardson DR (2006) Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. Blood 107: 2599
34. Trinder D, Oates PS, Thomas C, Sadleir J, Morgan EH (2000) Localisation of divalent metal transporter 1 (DMT1) to the microvillus membrane of rat duodenal enterocytes in iron deficiency, but to hepatocytes in iron overload. Gut 46: 270
35. Anderson GJ, Frazer DM (2005) Hepatic iron metabolism. Semin Liver Dis 25: 420
36. Gunshin H, Fujiwara Y, Custodio AO, Direnzo C, Robine S, Andrews NC (2005) Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 115: 1258
37. Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341: 1986
38. Hagler L, Askew EW, Neville JR, Mellick PW, Coppes RI Jr, Lowder JF Jr (1981) Influence of dietary iron deficiency on hemoglobin, myoglobin, their respective reductases, and skeletal muscle mitochondrial respiration. Am J Clin Nutr 34: 2169
39. Weiss G (2005) Modification of iron regulation by the inflammatory response. Best Pract Res Clin Haematol 18: 183
40. Theurl I, Ludwiczek S, Eller P, Seifert M, Artner E, Brunner P, et al (2005) Pathways for the regulation of body iron homeostasis in response to experimental iron overload. J Hepatol 43: 711
41. Ludwiczek S, Theurl I, Bahram S, Schumann K, Weiss G (2005) Regulatory networks for the control of body iron homeostasis and their dysregulation in HFE mediated hemochromatosis. J Cell Physiol 204: 489
42. Abouhamed M, Gburek J, Liu W, Torchalski B, Wilhelm A, Wolff NA, et al (2006) Divalent metal transporter 1 in the kidney proximal tubule is expressed in late endosomes/lysosomal membranes: implications for renal handling of protein-metal complexes. Am J Physiol Renal Physiol 290: F1525
43. Canonne-Hergaux F, Gros P (2002) Expression of the iron transporter DMT1 in kidney from normal and anemic mk mice. Kidney Int 62: 147
44. Wareing M, Ferguson CJ, Green R, Riccardi D, Smith CP (2000) In vivo characterization of renal iron transport in the anaesthetized rat. J Physiol 524 Pt 2: 581
45. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, et al (2002) An iron delivery pathway mediated by a lipocalin. Mol Cell 10: 1045
46. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, et al (2004) Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 15: 3073
47. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P (2004) Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24: 307
48. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365: 1231
49. Wareing M, Ferguson CJ, Delannoy M, Cox AG, McMahon RF, Green R, et al (2003) Altered dietary iron intake is a strong modulator of renal DMT1 expression. Am J Physiol Renal Physiol 285: F1050
50. Ganz T, Nemeth E (2006) Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 290: G199
51. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110: 1037
52. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1271
53. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 99: 4596
54. Viatte L, Nicolas G, Lou DQ, Bennoun M, Lesbordes-Brion JC, Canonne-Hergaux F, et al (2005) Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood 107: 2952
55. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M (2005) Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA 102: 1324
56. Nemeth E, Tattle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090
57. Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, et al (2005) Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 106: 746
58. Peyssonnaux C, Zinkernagel AS, Datta V, Lauth X, Johnson RS, Nizet V (2006) TLR-4 dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 107: 3727
59. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, et al (2006) Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38: 531
60. Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC (2005) A mouse model of juvenile hemochromatosis. J Clin Invest 115: 2187
61. Niederkofler V, Salie R, Arber S (2005) Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 115: 2180
62. Zoller H, Cox TM (2005) Hemochromatosis: genetic testing and clinical practice. Clin Gastroenterol Hepatol 3: 945
63. Beutler E, Hoffbrand AV, Cook JD (2003) Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program): 40
64. Pietrangelo A (2004) The ferroportin disease. Blood Cells Mol Dis 32: 131
65. Pietrangelo A, Caleffi A, Henrion J, Ferrara F, Corradini E, Kulaksiz H, et al (2005) Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 128: 470
66. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, et al (2003) Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 33: 21
67. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube MP, et al (2004) Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36: 77
68. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J, et al (2005) Hepcidin in iron overload disorders. Blood 105: 4103
69. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C (2005) Hepcidin is decreased in TFR2 hemochromatosis. Blood 105: 1803
70. Corsi B, Cozzi A, Arosio P, Drysdale J, Santambrogio P, Campanella A, et al (2002) Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism. J Biol Chem 277: 22430
71. Zoller H, Theurl I, Koch RO, McKie AT, Vogel W, Weiss G (2003) Duodenal cytochrome b and hephaestin expression in patients with iron deficiency and hemochromatosis. Gastroenterology 125: 746
72. Zoller H, Pietrangelo A, Vogel W, Weiss G (1999) Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Lancet 353: 2120
73. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC (2002) Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100: 3776
74. Pietrangelo A (2005) Non-HFE hemochromatosis. Semin Liver Dis 25: 450
75. Trinder D, Baker E (2003) Transferrin receptor 2: a new molecule in iron metabolism. Int J Biochem Cell Biol 35: 292
76. Wallace DF, Summerville L, Lusby PE, Subramaniam VN (2005) First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut 54: 980
77. Cemonesi L, Forni GL, Soriani N, Lamagna M, Fermo I, Daraio F, et al (2005) Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol 131: 663
78. Bosio S, De Gobbi M, Roetto A, Zecchina G, Leonardo E, Rizzetto M, et al (2002) Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood 100: 2246
79. Cox TM, Halsall DJ (2002) Hemochromatosis - neonatal and young subjects. Blood Cells Mol Dis 29: 411
80. O'Neil J, Powell L (2005) Clinical aspects of hemochromatosis. Semin Liver Dis 25: 381
81. Tavill AS (2001) Diagnosis and management of hemochromatosis. Hepatology 33: 1321
82. Brandhagen DJ, Fairbanks VF, Baldus W (2002) Recognition and management of hereditary hemochromatosis. Am Fam Physician 65: 853
83. Altes A, Remacha AF, Sureda A, Martino R, Briones J, Brunei S, et al (2003) Patients with biochemical iron overload: causes and characteristics of a cohort of 150 cases. Ann Hematol 82: 127
84. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105: 855
85. Nielsen P, Fischer R, Buggisch P, Janka-Schaub G (2003) Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol 123: 952
86. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y (1997) A new syndrome of liver iron overload with normal transferrin saturation. Lancet 349: 95
87. Mendier MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, et al (1999) Insulin resistance-associated hepatic iron overload. Gastroenterology 117: 1155
88. McNamara L, Gordeuk VR, MacPhail AP (2005) Ferroportin (Q248H) mutations in African families with dietary iron overload. J Gastroenterol Hepatol 20: 1855
89. Gordeuk V, Mukiibi J, Hasstedt SJ, Samowitz W, Edwards CQ, West G, et al (1992) Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 326: 95
90. Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, Castro O, et al (2003) Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 31: 299
91. Bonkovsky HL, Troy N, McNeal K, Banner BF, Sharma A, Obando J, et al (2002) Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 37: 848
92. Weiss G, Wachter H, Fuchs D (1995) Linkage of cell-mediated immunity to iron metabolism. Immunol Today 16: 495
93. Oexle H, Kaser A, Most J, Bellmann-Weiler R, Werner ER, Werner-Felmayer G, et al (2003) Pathways for the regulation of interferon-gamma-inducible genes by iron in human monocytic cells. J Leukoc Biol 74: 287
94. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, et al (1992) Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1. Exp Hematol 20: 605
95. Weiss G, Werner-Felmayer G, Werner ER, Grunewald K, Wachter H, Hentze MW (1994) Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 180: 969
96. Bird CL, Witte JS, Swendseid ME, Shikany JM, Hunt IF, Frankl HD, et al (1996) Plasma ferritin, iron intake, and the risk of colorectal polyps. Am J Epidemiol 144: 34
97. Huang X (2003) Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 533: 153
98. Shaheen NJ, Silverman LM, Keku T, Lawrence LB, Rohlfs EM, Martin CF, et al (2003) Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst 95: 154
99. Hellerbrand C, Poppl A, Hartmann A, Scholmerich J, Lock G (2003) HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol 1: 279
100. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al (2001) Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 33: 647
101. Wang SC, Lin KH, Chern JP, Lu MY, Jou ST, Lin DT, et al (2003) Severe bacterial infection in transfusion-dependent patients with thalassemia major. Clin Infect Dis 37: 984
102. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al (2005) A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with (beta)-thalassemia. Blood 107: 3455
103. Hershko C, Hoffbrand AV, Keret D, Souroujon M, Maschler I, Monselise Y, et al (2005) Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica 90: 585
104. Weiss G (2002) Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 16: 87
105. Weiss G, Gordeuk VR (2005) Benefits and risks of iron therapy for chronic anaemias. Eur J Clin Invest 35 [Suppl 3]: 36
106. Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL (1997) Prevalence of iron deficiency in the United States. Jama 277: 973
107. Umbreit J (2005) Iron deficiency: a concise review. Am J Hematol 78: 225
108. Schrier SD (2005) Treatment of anemia due to iron deficiency. UpToDate Edition 13.2 Vol 2005
109. Annibale B, Capurso G, Chistolini A, D'Ambra G, DiGiulio E, Monarca B, et al (2001) Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. Am J Med 111: 439
110. James MW, Chen CM, Goddard WP, Scott BB, Goddard AF (2005) Risk factors for gastrointestinal malignancy in patients with iron-deficiency anaemia. Eur J Gastroenterol Hepatol 17: 1197
111. Schrier SD (2005) Causes and diagnosis of anemia due to iron deficiency. UpToDate Edition 13.2 Vol 2005
112. Han AP, Yu C, Lu L, Fujiwara Y, Browne C, Chin G, et al (2001) Heme-regulated eIF2alpha kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency. Embo J 20: 6909
113. Idjradinata P, Pollitt E (1993) Reversal of developmental delays in iron-deficient anaemic infants treated with iron. Lancet 341: 1
114. Jacobs P, Wood L, Bird AR (2000) Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematol 5: 77
115. Harvey RS, Reffitt DM, Doig LA, Meenan J, Ellis RD, Thompson RP, et al (1998) Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther 12: 845
116. Nissenson AR, Berns JS, Sakiewicz P, Ghaddar S, Moore GM, Schleicher RB, et al (2003) Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 42: 325
117. Annibale B, Marignani M, Monarca B, Antonelli G, Marcheggiano A, Martino G, et al (1999) Reversal of iron deficiency anemia after helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 131: 668
118. DuBois S, Kearney DJ (2005) Iron-deficiency anemia and helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 100: 453
119. Afzali B, Goldsmith DJ (2004) Intravenous iron therapy in renal failure: friend and foe? J Nephrol 17: 487
120. Steurer M, Wagner H, Gastl G (2004) Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey. Wien Klin Wochenschr 116: 367
121. Roy CN, Andrews NC (2005) Anemia of inflammation: the hepcidin link. Curr Opin Hematol 12: 107
122. Ludwiczek S, Aigner E, Theurl I, Weiss G (2003) Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101: 4148
123. Tilg H, Ulmer H, Kaser A, Weiss G (2002) Role of IL-10 for induction of anemia during inflammation. J Immunol 169: 2204
124. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101: 2461
125. Liu XB, Nguyen NB, Marquess KD, Yang F, Haile DJ (2005) Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages. Blood Cells Mol Dis 35: 47
126. Lee P, Peng H, Gelbart T, Wang L, Beutler E (2005) Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 102: 1906
127. Lee P, Peng H, Gelbart T, Beutler E (2004) The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci USA 101: 9263
128. Macdougall IC, Cooper AC (2005) Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest 35 [Suppl 3]: 32
129. Theurl I, Mattle V, Seifert M, Mariani M, Marth C, Weiss G (2006) Dysregulated monocyte iron homeostasis and erythropoeitin formation in patients with anemia of chronic disease. Blood 107: 4142
130. Punnonen K, Irjala K, Rajamaki A (1997) Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 89: 1052
131. Horl WH, Holzer H, Mayer GJ (2002) Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study. Wien Klin Wochenschr 114: 967
132. Weiss G VRG, Hershko C (2005) Anemia of chronic disease. In: Cheson BD (ed) Basic and clinical oncology, Vol 30. CRC Press, Taylor & Francis Group, Boca Raton
133. Eschbach JW (2002) Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol 13: 1412
134. Eckardt KU (2001) Anemia in critical illness. Wien Klin Wochenschr 113: 84
135. Walsh TS, Lee RJ, Maciver CR, Garrioch M, Mackirdy F, Binning AR, et al (2006) Anemia during and at discharge from intensive care: the impact of restrictive blood transfusion practice. Intensive Care Med 32: 100
136. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, et al (2002) Anemia and blood transfusion in critically ill patients. Jama 288: 1499
137. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, et al (2004) The CRIT Study: Anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med 32: 39
138. Munoz M, Romero A, Morales M, Campos A, Garcia-Erce JA, Ramirez G (2005) Iron metabolism, inflammation and anemia in critically ill patients. A cross-sectional study. Nutr Hosp 20: 115
139. Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, Melot C, et al (1997) Erythropoietin response is blunted in critically ill patients. Intensive Care Med 23: 159
140. Scharte M, Fink MP (2003) Red blood cell physiology in critical illness. Crit Care Med 31: S651
141. Hobisch-Hagen P, Wiedermann F, Mayr A, Fries D, Jelkmann W, Fuchs D, et al (2001) Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med 29: 743
142. La Ferla K, Reimann C, Jelkmann W, Hellwig-Burgel T (2002) Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. Faseb J 16: 1811
143. Dybedal I, Jacobsen SE (1995) Transforming growth factor beta (TGF-beta), a potent inhibitor of erythropoiesis: neutralizing TGF-beta antibodies show erythropoietin as a potent stimulator of murine burst-forming unit erythroid colony formation in the absence of a burst-promoting activity. Blood 86: 949
144. Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P (1989) In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 73: 678
145. Wang CQ, Udupa KB, Lipschitz DA (1995) Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J Cell Physiol 162: 134
146. Baskurt OK, Gelmont D, Meiselman HJ (1998) Red blood cell deformability in sepsis. Am J Respir Crit Care Med 157: 421
147. du Cheyron D, Parienti JJ, Fekih-Hassen M, Daubin C, Charbonneau P (2005) Impact of anemia on outcome in critically ill patients with severe acute renal failure. Intensive Care Med 31: 1529
148. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, et al (2005) Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111: 2042
149. Keough-Ryan TM, Kiberd BA, Dipchand CS, Cox JL, Rose CL, Thompson KJ, et al (2005) Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis 46: 845
150. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM (2001) Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345: 1230
151. Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, et al (2005) Transfusion-related acute lung injury: definition and review. Crit Care Med 33: 721
152. Carson JL, Altman DG, Duff A, Noveck H, Weinstein MP, Sonnenberg FA, et al (1999) Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion 39: 694
153. Heiss MM, Mempel W, Delanoff C, Jauch KW, Gabka C, Mempel M, et al (1994) Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 12: 1859
154. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340: 409
155. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al (2002) Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. Jama 288: 2827
156. Silverberg DS, Wexler D, Blum M, Iaina A, Sheps D, Keren G, et al (2005) Effects of treatment with epoetin beta on outcomes in patients with anaemia and chronic heart failure. Kidney Blood Press Res 28: 41
157. Kosch M, Schaefer RM (2003) Indications and practical management of parenteral iron therapy. Wien Klin Wochenschr 115: 380
158. Atkinson PG, Blackwell JM, Barton CH (1997) Nramp1 locus encodes a 65 kDa interferon-gamma-inducible protein in murine macrophages. Biochem J 325: 779
159. Pritsche G, Dlaska M, Barton H, Theurl I, Garimorth K, Weiss G (2003) Nramp1 functionality increases inducible nitric oxide synthase transcription via stimulation of IFN regulatory factor 1 expression. J Immunol 171: 1994
160. Shaw GC, Cope JJ, Li L, Corson K, Hersey C, Ackermann GE, et al (2006) Mitoferrin is essential for erythroid iron assimilation. Nature 440: 96
161. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al (2003) L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9: 1187
162. Chen H, Attieh ZK, Su T, Syed BA, Gao H, Alaeddine RM, et al (2004) Hephaestin is a ferroxidase that maintains partial activity in sex-linked anemia mice. Blood 103: 3933
163. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et al (2000) Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403: 776
164. Feder JN (1999) The hereditary hemochromatosis gene (HFE): a MHC class I-like gene that functions in the regulation of iron homeostasis. Immunol Res 20: 175
165. Fleming MD, Trenor CC 3rd, Su MA, Foernzler D, Beier DR, Dietrich WF, et al (1997) Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 16: 383
166. Fleming RE, Bacon BR (2005) Orchestration of iron homeostasis. N Engl J Med 352: 1741
167. Gunshin H, Starr CN, Direnzo C, Fleming MD, Jin J, Greer EL, et al (2005) Cybrd1 (duodenal cytochrome b) is not necessary for dietary iron absorption in mice. Blood 106: 2879
168. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al (2000) A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 5: 299
169. Schaer DJ, Schaer CA, Buehler PW, Boykins RA, Schoedon G, Alayash AI, et al (2006) CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 107: 373
170. Theil EC (2003) Ferritin: at the crossroads of iron and oxygen metabolism. J Nutr 133: 1549S
171. Anderson GJ, Frazer DM, McKie AT, Vulpe CD, Smith A (2005) Mechanisms of haem and non-haem iron absorption: lessons from inherited disorders of iron metabolism. Biometals 18: 339
172. Knutson M, Wessling-Resnick M (2003) Iron metabolism in the reticuloendothelial system. Crit Rev Biochem Mol Biol 38: 61
173. Ludwiczek S, Theurl I, Artner-Dworzak E, Chorney M, Weiss G (2004) Duodenal HFE expression and hepcidin levels determine body iron homeostasis: modulation by genetic diversity and dietary iron availability. J Mol Med 82: 373
174. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, et al (2005) Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115: 610
175. Whitington PF, Malladi P (2005) Neonatal hemochromatosis: is it an alloimmune disease? J Pediatr Gastroenterol Nutr 40: 544
176. Ponka P (2002) Rare causes of hereditary iron overload. Semin Hematol 39: 249
177. Kawashima A, Oda Y, Yachie A, Koizumi S, Nakanishi I (2002) Heme oxygenase-1 deficiency: the first autopsy case. Hum Pathol 33: 125
178. Kato J, Fujikawa K, Kanda M, Fukuda N, Sasaki K, Takayama T, et al (2001) A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 69: 191
179. Mims MP, Guan Y, Pospisilova D, Priwitzerova M, Indrak K, Ponka P, et al (2005) Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 105: 1337
180. Beaumont C, Delaunay J, Hetet G, Grandchamp B, de Montalembert M, Tchernia G (2006) Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood 107: 4168
181. Iolascon A, d'Apolito M, Servedio V, Cimmino F, Piga A, Camaschella C (2006) Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 107: 349
182. Miyajima H (2003) Aceruloplasminemia, an iron metabolic disorder. Neuropathology 23: 345
183. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH (1999) Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 116: 193
184. Adams PC, Deugnier Y, Moirand R, Brissot P (1997) The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 25: 162
185. Adams PC, Chakrabarti S (1998) Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology 114: 319
186. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G (1996) Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110: 1107
187. Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, Adams PC (2002)
188. Evens AM, Mehta J, Gordon LI (2004) Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant 34: 561
189. Fargion S (1999) Dysmetabolic iron overload syndrome. Haematologica 84: 97
190. Rund D, Rachmilewitz E (2005) Beta-thalassemia. N Engl J Med 353: 1135
191. Larrick JW, Hyman ES (1984) Acquired iron-deficiency anemia caused by an antibody against the transferrin receptor. N Engl J Med 311: 214